Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast reported early real-world commercial data showing that 84% of the first 25 pediatric patients with steroid-refractory acute graft-versus-host disease treated with its FDA-approved therapy Ryoncil survived and completed the initial 28-day treatment course, consistent with prior clinical experience and reinforcing the importance of rapid initiation after steroid resistance. The company has moved quickly to build out market access and adoption, onboarding 45 U.S. transplant centers toward a 64-center target that covers most domestic transplants, securing broad public and private payer coverage supported by a dedicated patient access hub, and leveraging this commercial foundation as it prepares a pivotal trial to extend Ryoncil’s label to adults with severe SR-aGvHD, a significantly larger market, in collaboration with the NIH-funded Bone Marrow Transplant Clinical Trials Network.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company specializing in allogeneic, off-the-shelf cellular medicines for severe and life-threatening inflammatory conditions, built on proprietary mesenchymal lineage cell therapy platforms remestemcel-L and rexlemestrocel-L. Its lead commercial product, Ryoncil, is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, and the company is also developing cell therapies for adult SR-aGvHD, biologic-resistant inflammatory bowel disease, heart failure and chronic low back pain, supported by a large global patent portfolio and manufacturing operations across Australia, the United States and Singapore.
Average Trading Volume: 4,104,358
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.46B
Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.